Announcements Trials
Browse Landscape

Status

Completed 2

Sponsor Class

OTHER 4INDUSTRY 2OTHER_GOV 1

Study Type

Observational 2

Sponsor

Conditions

Inflammatory Bowel Diseases 1Crohn Disease 1Colitis, Ulcerative 1Autoimmune Diseases 1Arthritis, Rheumatoid 1

Interventions

pembrolizumab 1029Carboplatin 966Paclitaxel 941Gemcitabine 798Cisplatin 754Docetaxel 697Bevacizumab 638Nivolumab 519Pemetrexed 507Capecitabine 475Cyclophosphamide 468Fluorouracil 424Dexamethasone 409Rituximab 391Oxaliplatin 351Injections 344Trastuzumab 313atezolizumab 311Cetuximab 291Leucovorin 288Irinotecan 269130-nm albumin-bound paclitaxel 255Prednisone 250Ipilimumab 244Doxorubicin 241Lenalidomide 231Fulvestrant 226fludarabine 215durvalumab 211Erlotinib Hydrochloride 196

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

2 trials
RecentStart dateEnrollment
INDUSTRY × CT-P13 × Clear all
NCT03452501 2021-02-23

Safety and Effectiveness Study of Remsima® in the Treatment of Inflammatory Bowel Diseases Among Saudi Arabia Patients

Hikma Pharmaceuticals LLC

Completed
157 enrolled

Colitis, Ulcerative, Crohn Disease, Inflammatory Bowel Diseases

NCT03348046 2020-03-04

PASSRRA

Hikma Pharmaceuticals LLC

Completed
22 enrolled

Arthritis, Rheumatoid, Autoimmune Diseases

Data powered by HemOnc (CC BY 4.0) Colophon âš¡